Methods for treating neurological disorders
Slow intrathecal administration of therapeutic cells within specific volume and concentration ranges addresses side effects, improving delivery and efficacy for neurodegenerative disease treatment.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- サイトラ リミテッド
- Filing Date
- 2024-07-18
- Publication Date
- 2026-07-23
AI Technical Summary
Existing intrathecal administration methods for delivering therapeutic cells to treat neurodegenerative diseases are limited by adverse events such as back pain, lower limb pain, and cell aggregation near the injection site, which increase with higher doses, reducing therapeutic efficacy.
A method involving slow intrathecal administration of a therapeutic cell suspension at a rate of 0.1 to 2 ml/min, with a volume within ±5 ml of the collected cerebrospinal fluid, and cell concentrations ranging from 1×10^6 to 5×10^7 cells/ml, to minimize side effects and enhance therapeutic delivery to the central nervous system.
This approach reduces side effects like back pain and cell aggregation, allowing for higher cell concentrations and doses to reach the brain, thereby improving therapeutic efficacy by enhancing cell dispersion and attachment along the spinal cord.
Smart Images
Figure 2026524667000001 
Figure 2026524667000002 
Figure 2026524667000003